CJC 1295 | 5mg without DAC + IPA | 5mg (10mg)

CJC-1295 (No DAC) + Ipamorelin – Synergistic Growth Axis Research Peptide

Overview:
CJC-1295 (without DAC) combined with Ipamorelin offers a synergistic pairing of two well-known research peptides that act on the growth hormone axis. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective growth hormone secretagogue. Together, they have been studied in in-vitro models for their potential to stimulate GH release with minimal activity on other hormonal pathways.

This combination is frequently explored in research investigating pulsatile growth hormone secretion, pituitary signaling, and endocrine regulation in controlled lab environments.

Chemical Information
CJC-1295 Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆
CJC-1295 Molecular Weight: 3,364.88 g/mol
Ipamorelin Molecular Formula: C₃₈H₄₉N₉O₅
Ipamorelin Molecular Weight: 711.85 g/mol
Form: Lyophilized Powder (Blended)
Purity: ≥99%
Storage: Store in a cool, dry place at -20°C. Protect from light.

Key Benefits (Research Use Only):

• Supports in-vitro modeling of GH pulsatility and pituitary response
• May enhance growth hormone release in research environments
• Combines GHRH analog and secretagogue activity for synergistic signaling
• Ideal for studies focused on growth, recovery, and hormone regulation

Research Applications
This peptide blend is commonly used in research exploring:

• Growth hormone stimulation pathways
• Pulsatile GH secretion modeling
• Endocrine system signaling and pituitary function
• Recovery and cellular repair mechanisms in-vitro

Product Usage & Compliance Notice
This compound is intended strictly for laboratory research purposes only. It is not a drug, food, or cosmetic, and is not for human or veterinary use. Any bodily introduction is strictly prohibited by law.

Product may only be handled by qualified professionals.
All product content is provided for educational and scientific reference only.
Do not misbrand, misuse, or misrepresent this product.

Patent & Trademark Notice
CJC-1295 is a patented compound originally developed by ConjuChem Biotechnologies. Any reference to CJC-1295 or Ipamorelin is strictly for informational purposes regarding availability as research compounds. These products are not manufactured, endorsed, or approved by any brand or patent holder.